other material
confidence high
sentiment positive
materiality 0.80
Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours
SUPERNUS PHARMACEUTICALS, INC.
- SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.
- By Day 10, response rate improved to 84.2% and remission to 63.2% in adults with major depressive disorder.
- Company notes positive early data; continues development and discussions with potential partners for Sunseeker asset.